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ABSTRACT
Cisplatin and carboplatin are effective antineoplastic agents. They are
also considered to be potentially highly ototoxic. To date, no long-term
follow-up data from well-documented cohorts with substantial num-
bers of childhood cancer survivors (CCS) with platinum-related hearing
loss are available. Therefore, in this study, we studied the reversibility
of ototoxicity from discontinuation of treatment onwards in a national
cohort of platinum-treated survivors with hearing loss at the end of
cancer treatment. Of the 168 CCS with follow-up audiograms, we lon-
gitudinally evaluated the course of hearing function in 61 CCS who
showed hearing impairment at discontinuation of treatment according
to the Münster criteria (>20 dB at 4–8 kHz). Survivors were treated
with platinum (median total cumulative dose cisplatin: 480 mg/m2 and
median total cumulative dose carboplatin: 2520mg/m2). Median follow-
up time was 5.5 years (range: 1.0–28.8 years). The results showed that
none of these survivors revealed improvement of hearing function even
till 28.8 years after discontinuation of treatment (grade<2bduring long-
term follow-up). An increase in hearing loss with two or three Münster
degrees was observed in five of 61 survivors after 1.6–19.6 years. Over-
all, this indicates that ototoxicity after platinum treatment may be irre-
versible and that longitudinal clinical audiological monitoring and care
is required in long-term survivors of childhood cancer on a large scale.
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Introduction
As survival rates of children with platinum-treated solid tumors have substantially improved,
the understanding of both short- and long-term side effects of platinum treatment becomes
increasingly important. Ototoxicity has been reported as a severe potential side effect of plat-
inum agents [1–3]. Platinum-induced ototoxicity is characterized by high-frequency sen-
sorineural hearing loss, and newer audiologic methods such as extended high-frequency
audiometry show that hearing loss can already occur at 12 kHz. This can subsequently
progress during treatment toward hearing loss at lower frequencies involved in speech (0.5–
6 kHz), of which 1–2 kHz frequencies are most important for speech. Consequently, ototox-
icity may lead to a delay in speech, language, and social-emotional development in children,
and subsequently it contributes to learning and developmental difficulties [4, 5].
To date, only scarce data are available on the longitudinal development of hearing impair-
ment from discontinuation of treatment toward later in life. Ototoxicity most often appears
during therapy. Nine studies included follow-up data on the course of hearing function after
platinum treatment in childhood cancer survivors (Table 1). However, these studies were rel-
atively small and did not report the influence of environmental factors such as the coexis-
tence of middle ear problems or head trauma. Other reports comprised small series and case-
reports of childhood cancer survivors with ototoxicity [6–9]. Studies including larger number
of patients with hearing loss that investigate the reversibility of hearing loss during long-term
follow-up are lacking.
In the current study, we prospectively evaluated the course of serious hearing impairment
at the time of completion of treatment after long-term follow-up in platinum-treated pediatric
CCS based on a national cohort.
Materials andmethods
This study aims to describe the course of hearing function in long-term survivors of child-
hood cancer that revealed ototoxicity at discontinuation of treatment. The assessment of
determinants of ototoxicity after platinum treatment is subject of another study by the Dutch
Childhood Oncology Group (DCOG)—Long-term Effects after Childhood Cancer (LATER)
group [10].
We performed a cross-sectional, multicenter study in long-term survivors of childhood
cancer who received platinum agents but not cranial irradiation, diagnosed between April
1980 and September 2012. The study was approved by the local medical ethical committee of
the ErasmusMedical Center, Rotterdam, the Netherlands (MEC-2015-269, EMC). Treatment
details, as well as patient characteristics, were retrieved from databases andmedical records of
all seven pediatric oncology centers in theNetherlands as part of theDCOGLATER study.We
excluded survivors with known pre-existing persistent hearing impairment at start therapy, as
well as those who had received cranial or local irradiation to the ear/neck region.We included
platinum-treated patients with clinical relevant hearing loss at discontinuation of platinum
treatment, as defined by Münster grade2b (>20 dB at4–8 kHz) [11].
Pure tone audiometry (PTA) was used to evaluate hearing function in children over 5 years
of age. PTA is performed at six different frequencies (0.25, 0.5, 1, 2, 4, and 8 kHz) in both
ears. Conditioned play audiometry was used for children from approximately age 2 years
onward, and visual reinforcement audiometry was used for children aged between 6 months
and 2 years. The co-existence of middle ear problems was excluded by further audiological
measures and tests. Patients with unreliable tests were also excluded. All audiograms were
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Table . Münster and SIOP Boston classiﬁcation for platinum-induced ototoxicity.
Grade Münster classiﬁcation
Audiological assessment according to
WHO classiﬁcation SIOP Boston classiﬁcation
  dB HL at all frequencies No considerable damage  dB HL at all frequencies
 > and dB HL at one or
more frequencies
Questionable, commencing damage > dB HL> kHz
 > dB HL at kHz Moderate damage > dB HL at kHz
a > – dB
b > – dB
c > dB
 > dB HL at<  kHz Impaired compensable with hearing
aid
> dB HL at kHz
a > – dB
b > – dB
c > dB
  dB at<  kHz Loss of function, compensable by
cochlear implantation
> dB HL at kHz
Abbreviations: HL= hearing loss, SIOP= International Society of Pediatric Oncology, WHO=World Health Organization
interpreted by a well-trained investigator (EC). For quality control, a random sample of 10%
of the audiograms was examined by a second, independent, international experienced audi-
ologist (AaZ-D). Hearing impairment was evaluated using Münster grading system (Table 2)
[11]. The Münster’s grading system was used as it is considered as providing the highest sen-
sitivity, specificity, and positive and negative predictive value compared to other ototoxicity
classification systems [12, 13]. In addition, the International Society of Pediatric Oncol-
ogy (SIOP) Boston grading system was used as a secondary, independent validation
[11, 14]. The SIOP Boston scale is considered a useful scale for studies of platinum-induced
ototoxicity [11, 14].
Significant improvement in hearing function was defined as a return to <Münster 2b at
follow-up. Aggravation of hearing impairment was defined as >1 (Münster) scale increase.
Audiograms performed within 1 year after discontinuation of platinum treatment were used
as baseline audiograms. Audiograms performed more than 1 year after discontinuation of
platinum treatment were used as follow-up audiograms.
Results
The study population consists of CCS treated at the Erasmus Medical Center, Rotterdam,
the Netherlands and a cohort of CCS treated between 1963 and 2002 as part of the DCOG
LATER study. The included cohort consists of CCS treated with platinum who were not
cranial irradiated and with an audiogram <1 year after discontinuation of platinum treat-
ment (n = 285). In 117 of these 285 survivors, no follow-up audiograms were performed
(Figure 1). The remaining 168 survivors were included in the analysis with one or more
audiograms after discontinuation of treatment (Figure 1). The survivors with follow-
up audiograms (n = 168) were not different with respect to age at diagnosis, gender, and
diagnosis than survivors without follow-up audiograms (n= 117). In contrast, survivors with
audiograms received a slightly higher median total cumulative dose cisplatin (480 mg/m2
vs. 408 mg/m2, p = 0.044) and were more often treated with cisplatin than carboplatin
(p = 0.031). Of the 168 survivors with follow-up audiograms, 61 (36.3%) had hearing
impairment at discontinuation of treatment (Münster grade 2b). CCS were diagnosed
with sarcoma (59%), neuroblastoma (18%), hepatoblastoma (9.8%), germ cell tumor (8.2%),
low-grade glioma (3.3%), and nephroblastoma (1.6%). Median age at diagnosis was 9.4 years
6 E. CLEMENS ET AL.
Figure . Flow chart of childhood cancer survivorswith hearing impairment at discontinuation of treatment.
(range: 0.1–17.2 years). Follow-up time ranged between 1.1 and 27.2 years after completion
of treatment, with a median of 5.9 years. Forty-six CCS had been treated with cisplatin only
at a median cumulative dose of 480 mg/m2 (range: 180–900 mg/m2). Two CCS had been
treated with carboplatin only at a cumulative dose of 1288 and 3230 mg/m2. The remaining
thirteen CCS had been treated with both platinum agents. The median cumulative dose of
cisplatin received was 400 mg/m2 (range: 300–570 mg/m2), and the median cumulative dose
of carboplatin received was 1700 mg/m2 (range: 992–3938 mg/m2 (Table 3).
Among the 61 CCSwithMunster grade2b hearing impairment,Münster score remained
unaltered over time in 32 survivors after a median time of 5.1 years (range 1.1–21.3 years;
Figure 2a and Supplementary Table S1). A subset of 24 CCS showed one Münster grade
increase after a median time of 3.5 years (range: 1.1–21.3 years). After a median time of
2.1 years (range 1.6–9.9 years), three CCS showed an increase of two Münster grades and
after a median time of 12.4 years (range 5.2–19.6), two survivors showed an increase of three
Münster grades (Figure 2b, Supplementary Table S1). There are no significant risk factors for
Table . Characteristics of the survivors.
Hearing impairment n= 
Age at diagnosis, median years (range) . (.–.)
Gender, n (%)
Male  (.)
Female  (.)
Childhood malignancy, n (%)
Sarcoma
∗
 ()
Brain tumor  (.)
Hepatoblastoma  (.)
Neuroblastoma  ()
Nephroblastoma  (.)
Germ cell tumor  (.)
Hodgkin lymphoma —
Platinum compound, n (%)
Cisplatin  (.)
Carboplatin  (.)
Both  (.)
Total cumulative dose, mg/m (range)
Cisplatin only  (-)
Carboplatin only
∗∗
 and 
Cisplatin both  (-)
Carboplatin both
∗∗
 (-)
Abbreviations: FU= follow-up, TCD= total cumulative dose
∗Osteosarcoma and rhabdomyosarcoma
∗∗/ CCS treated with carboplatin only were not treated with autologous stem cell transplantation (ASCT); / CCS treated
with both platinum compounds received high-dose carboplatin (– mg/m) as part of ASCT; / treated with both
platinum compounds were not treated with ASCT (– mg/m carboplatin).
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Figure . Childhood cancer survivors with hearing impairment at discontinuation of treatment (Münster
b). Survivors with hearing impairment that persisted with equal severity (A). Survivors with aggravating
hearing impairment over time (B). Survivors with> grade loss over time are depicted in red and indicated
by an asterisk. Hearing did not recover in any of the survivors.
developing none vs. 2 grades of hearing impairment over time. In none of the survivors,
Münster score improved over time.
Using the SIOP Boston scale, 53/168 (32%) of the CCS had hearing impairment at dis-
continuation of treatment. Among these 53 survivors with SIOP Boston grade 2 hearing
impairment, SIOP Boston score remained unaltered over time in 47 survivors after a median
time of 9 years (range 1.1–21.3 years; Supplementary Table S1). A subset of 5 CCS showed one
SIOP Boston scale increase after a median time of 3.8 years (range: 1.6–24.7 years) and one
CCS showed two SIOP Boston scales increase after 1.1 years. Similar to the Münster criteria,
in none of the survivors, SIOP Boston scale improved over time.
Discussion
The purpose of this study was to reveal the course of hearing loss during long-term follow-up
in a cohort of CCSwith hearing impairment at time of discontinuation of platinum treatment.
Although the risk of platinum-related hearing loss is common knowledge, so far long-term
follow-up data on the (ir)reversibility of hearing impairment are scarce and are based on lim-
ited numbers and incomplete data. In the current study, we showed that none of the survivors
of childhood cancer with clinical relevant hearing impairment according to bothMünster and
SIOP Boston scale at discontinuation of treatment demonstrated recovery of hearing function
to better ranges (Münster grade<2b or SIOP Boston grade<2) during follow-up. This indi-
cates that hearing impairment is irreversible on the long termwith its attendant consequences
for speech development, social-emotional development, and learning development.
This finding is in agreement with those of previous literature describing the pathophysiol-
ogy of platinum-induced ototoxicity in mice, [15, 16] which shows that cisplatin causes DNA
lesions by forming intrastrand and interstrand crosslinks, activating several signal transduc-
tion pathways. In vitro, this results in the activation of apoptosis [17]. Furthermore, cisplatin
induces reactive oxygen species formation, leading to apoptosis of the hair cells [15, 18]. The
consequently degenerated cochlear inner and outer hair cells, once damaged, are suggested
not to have the potential to regenerate.
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In five of the 61 survivors, we found serious aggravation of hearing loss (two or three
degrees of severity) after 1.6–19.6 years. These survivors with2 grade hearing loss over time
were all women, whereas in the total cohort, women only represent 48%. Theywere diagnosed
between 9 and 12.7 years of age with neuroblastoma (n= 1), osteosarcoma (n= 2), and germ
cell tumor (n = 2).
In our study, no detailed information about noise exposure, or use of ototoxic medica-
tion after discontinuation of treatment, could be retrieved because of the cross-sectional
design of the study. In future studies, prospective collection of such confounding factors
may be of value in the identification of survivors for early monitoring of hearing impair-
ment in the future. Timing of audiometric testing was not equal among survivors, and
follow-up audiograms varied between CCS, from 1.6 to 21.3 years after the end of treat-
ment. On one hand, survivors with a late follow-up audiogram could have progression of
hearing loss already early after the first follow-up audiogram. On the other hand, survivors
with brief follow-up could have progression of hearing loss at a later time point that was
missed.
We are the first to report the irreversibility of hearing loss after platinum treatment in a
well-documented substantial cohort of platinum-treated survivors of childhood cancer that
were noncranial irradiated. Our study confirms the results of a previous smaller study in
13 CCS, which showed that hearing loss is indefinite [19]. To date, only a few studies have
issued the course of platinum-induced hearing loss during follow-up [6–8, 20–22]. These
studies included limited number of patients, [6–8, 21] included cranial irradiated patients,
[8, 20, 21] and did only cover one or two platinum-treated malignancy types [20–22]. Nitz
et al. studied children with osteosarcoma and soft-tissue sarcoma and identified 55/112
with hearing loss (<4 kHz and 4 kHz). Of these, 51 showed no recovery of function and
four showed improvement of hearing function over time. However, it was not described if
hearing function improved to normal hearing ranges [20]. Qaddoumi et al. [21] suggested
that in 2/12 retinoblastoma patients treated with carboplatin, hearing impairment (Brock
grade 1 and grade 4) resolved, but it was unsure up to what level. Stohr et al. [22] described a
frequency of 20/42 osteosarcoma patients with hearing impairment after discontinuation of
cisplatin treatment. After a median follow-up time of 5.5 years, 18 patients had permanent
hearing loss. Only 2/20 showed hearing improvement to <grade 2 (self-designed scoring
system). Confounding factors with regard to infection and co-medication were not taken into
account in any report at time of assessment of hearing function. An unpublished study by
Dutton et al. [23] reported 14 patients without recovery of hearing function at 2.5–10 years
after treatment. Although some of these studies do not seem to be in line with our results,
improvement of hearing function to normal values has never been well documented after
initial hearing loss in the range of Münster grade 2b or equal levels of hearing loss using
other classification methods (e.g. Brock or Chang) [20–22].
We conclude from our study in noncranial irradiated pediatric patients that the risk of per-
manent platinum-related hearing loss is substantial when this is confirmed at the end of can-
cer treatment. Although this hearing loss is constant in most cases, 30 survivors even showed
aggravation (1 Münster grade). Therefore, clinical surveillance is necessary before more
significant frequencies for speech perception are affected. On an international level (Interna-
tional Guideline Harmonization Group (IGHG)), in collaboration with the survivors group
of PanCare, clinical surveillance guidelines for long-term follow-up of hearing loss in child-
hood cancer survivors are nowbeing harmonized. This will aid in the awareness of health-care
providers of this cancer-related permanent high-impact treatment-related health risk andwill
guide optimum care for survivors.
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